TimesSquare Capital Management LLC Takes $48.69 Million Position in Ionis Pharmaceuticals, Inc. $IONS

Posted by Brian Himes on Aug 18th, 2026

TimesSquare Capital Management LLC purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 614,070 shares of the company’s stock, valued at approximately $48,690,000. TimesSquare Capital Management LLC owned 0.37% of Ionis Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Capital World Investors lifted its stake in Ionis Pharmaceuticals by 41.2% in the fourth quarter. Capital World Investors now owns 17,961,299 shares of the company’s stock valued at $1,420,918,000 after buying an additional 5,238,571 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Ionis Pharmaceuticals by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 3,148,849 shares of the company’s stock worth $249,158,000 after acquiring an additional 82,560 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Ionis Pharmaceuticals by 9.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,987,840 shares of the company’s stock worth $236,370,000 after acquiring an additional 258,155 shares during the period. Baker BROS. Advisors LP increased its holdings in shares of Ionis Pharmaceuticals by 216.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,791,841 shares of the company’s stock worth $141,753,000 after acquiring an additional 1,225,043 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Ionis Pharmaceuticals by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,541,841 shares of the company’s stock valued at $121,975,000 after purchasing an additional 21,890 shares during the last quarter. Institutional investors own 93.86% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wall Street Zen downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Canaccord Genuity Group cut their target price on Ionis Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Leerink Partners boosted their price target on Ionis Pharmaceuticals from $122.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. TD Cowen reissued a “buy” rating and issued a $108.00 price target on shares of Ionis Pharmaceuticals in a research note on Monday, June 15th. Finally, Oppenheimer reissued an “outperform” rating and set a $111.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday, April 30th. Eighteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $94.65.

Get Our Latest Stock Analysis on Ionis Pharmaceuticals

Ionis Pharmaceuticals Price Performance

NASDAQ:IONS opened at $58.63 on Tuesday. The company has a quick ratio of 7.73, a current ratio of 7.89 and a debt-to-equity ratio of 3.07. The business’s 50-day moving average price is $65.32 and its 200 day moving average price is $72.73. Ionis Pharmaceuticals, Inc. has a 52-week low of $41.71 and a 52-week high of $86.74. The firm has a market cap of $9.74 billion, a P/E ratio of -16.95 and a beta of 0.41.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.39. The company had revenue of $267.95 million during the quarter, compared to the consensus estimate of $189.10 million. Ionis Pharmaceuticals had a negative net margin of 64.76% and a negative return on equity of 111.08%. Ionis Pharmaceuticals’s revenue was down 40.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.70 EPS. As a group, sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -3.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Michael R. Hayden bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $51.60 per share, with a total value of $258,000.00. Following the completion of the purchase, the director directly owned 24,000 shares in the company, valued at approximately $1,238,400. This trade represents a 26.32% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Brett P. Monia sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $80.59, for a total transaction of $4,029,500.00. Following the sale, the chief executive officer owned 245,571 shares of the company’s stock, valued at $19,790,566.89. The trade was a 16.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 233,163 shares of company stock valued at $18,316,551. Corporate insiders own 1.81% of the company’s stock.

Ionis Pharmaceuticals Company Profile

(Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.